Unique ID issued by UMIN | C000000006 |
---|---|
Receipt number | R000000009 |
Scientific Title | Lisinopril only and a combination of lisinopril and losartan for IgA nephropathy with focal mesangial proliferation in children: A randomized controlled trial of efficacy and safety |
Date of disclosure of the study information | 2005/08/01 |
Last modified on | 2013/12/25 10:02:18 |
Lisinopril only and a combination of lisinopril and losartan for IgA nephropathy with focal mesangial proliferation in children: A randomized controlled trial of efficacy and safety
Lisinopril only and a combination of lisinopril and losartan: A randomized controlled trial(JSKDC01)
Lisinopril only and a combination of lisinopril and losartan for IgA nephropathy with focal mesangial proliferation in children: A randomized controlled trial of efficacy and safety
Lisinopril only and a combination of lisinopril and losartan: A randomized controlled trial(JSKDC01)
Japan |
IgA nephropathy in children
Nephrology | Pediatrics |
Others
NO
By comparing lisinopril only and a combination of lisinopril and losartan, the better is selected as a standard treatment for IgA nephropathy in children in our group.
Safety,Efficacy
Disappearance rate of proteinuria
Interventional
Parallel
Randomized
Open -but assessor(s) are blinded
Active
2
Treatment
Medicine |
Lisinopril for 2 years
Lisinopril+losartan for 2 years
2 | years-old | <= |
18 | years-old | >= |
Male and Female
1.Biopsy diagnoses of IgA nephropathy with focal mesangial proliferation, where a renal biopsy has been performed within 4 months before eligibility.
2.Proteinuria with a urinary protein-creatinine ratio >0.2.
4.Aged 2 to 18 years.
5.Written informed consent from the patients' parents or legal guardians.
1.Other renal or systemic forms of nephrotic syndrome defined on renal biopsy, clinical features or serology (Henoch-Schönlein nephritis, systemic lupus erythematosus).
2.Medical history of allergy or hypersensitivity reactions to lisinopuril and losartan.
3.Chronic renal dysfunction.
4.Active infectious disease.
5.Severe liver disfunction.
6.History of steroid, immunosupression, ACEI and ARB administration.
7.History of Saireito or dipilidamol administration.
8.Pregnancy.
9.Judged inappropriate for this study by the physicians.
110
1st name | |
Middle name | |
Last name | Norishige Yoshikawa |
Wakayama Medical University
Department of Pediatrics
811-1 Kimiidera Wakayama City Wakayama
073-441-0633
nori@wakayama-med.ac.jp
1st name | |
Middle name | |
Last name | Nakanishi |
Japanese Study Group of Kidney Disease in Children
Department of Pediatrics, Wakayama Medical University
811-1 KImiidera Wakayama City
073-441-0633
jskdc@wakayama-med.ac.jp
Japanese Study group of Kidney Disease in Children
The Ministry of Health,Labour and Welfare
NO
2005 | Year | 08 | Month | 01 | Day |
Unpublished
Completed
2004 | Year | 11 | Month | 30 | Day |
2005 | Year | 01 | Month | 01 | Day |
2013 | Year | 12 | Month | 01 | Day |
2005 | Year | 06 | Month | 14 | Day |
2013 | Year | 12 | Month | 25 | Day |
Value
https://center6.umin.ac.jp/cgi-open-bin/ctr_e/ctr_view.cgi?recptno=R000000009
Research Plan | |
---|---|
Registered date | File name |
Research case data specifications | |
---|---|
Registered date | File name |
Research case data | |
---|---|
Registered date | File name |